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Lowering Therapy
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sNumerous studies over the past 2 decades have
demonstrated the benefit of low-density lipoprotein
(LDL) cholesterol lowering on heart attack, stroke,
and cardiac death (1). Both invasive and noninva-
sive imaging approaches have been used as surro-
gate markers to demonstrate benefits of LDL low-
ering on atherosclerosis. Studies using intravascular
ultrasonography (IVUS) of the coronary arteries
have demonstrated that statin initiation is associated
See page 977
with halting of plaque progression, and, in fact,
with more potent statins, evidence of plaque regres-
sion (2). Carotid intima-media thickness studies
with ultrasonography have likewise demonstrated
benefit of statin therapy (3). These studies have
primarily been conducted over the first year or 2
after initiation of statins, and the endpoint used has
been coronary plaque volume or greatest plaque area
in the case of IVUS and carotid wall thickness in
the case of carotid intima-media thickness. Nonin-
vasive imaging with magnetic resonance imaging
(MRI) of the carotid and aorta (4–6) and superfi-
cial femoral artery (7) have demonstrated the plaque
regression capabilities of these powerful drugs.
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this paper to disclose.A decade ago, Crisby et al. (8) showed that statin
reatment was associated with lower lipid compo-
ents in atherosclerosis in ex vivo carotid specimens
xcised at the time of endarterectomy. Clear dem-
nstration of this effect in vivo in humans required
urther development in noninvasive imaging of
laque components. The groups at the University of
ashington and at Mount Sinai, among others,
ave validated the technique of plaque composition
elineation by carotid MRI over the past 10 to 15
ears, specifically the ability to differentiate lipid,
brous, calcified, and hemorrhagic components (9–
2) The benefits of lipid lowering on plaque mor-
hology was suggested in a carotid MRI study from
hao et al. (13) in a post-hoc study of 16 patients
t the end of the FATS (Familial Atherosclerosis
reatment Study) study, in which patients treated
ith an aggressive lipid-lowering regimen had less
ipid and more calcium in their plaque as compared
o control subjects. A prospective study from this
roup (14) in another small study of 18 patients
howed that rosuvastatin in either high dose or low
ose reduced the extent of lipid-rich necrotic core
LRNC) by 41%, although plaque volume did not
hange in either group. However, the effect of
ipid-lowering therapy on changes in atherosclerotic
laque composition measured by MRI over time
as not been fully delineated. In addition, the
elative effect of statins compared to other lipid-
owering drugs has not been previously illustrated.
This sets the stage for the Zhao et al. (15) paper
n this issue of iJACC. They present intriguing data
ith regard to the effect of lipid-lowering therapy
n changes in atherosclerotic plaque composition
easured by carotid MRI over time. Patients in this
tudy comprise part of a 3-arm study of lipid-
owering strategies involving 123 patients. To be
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988entered into the study, patients had to have estab-
lished coronary or carotid disease, elevated apolipo-
protein B, and prior lipid-lowering therapy of
1-year duration. Patients were then randomly
assigned to either atorvastatin alone, atorvastatin
plus extended-release niacin, or triple therapy with
the addition of colesevelam to the regimen. Serial
MRI scans were performed at baseline, and yearly
for 3 years. Only the 33 patients who had
evidence of LRNC in their carotid plaque at
baseline were evaluated in this paper. Plaque
volume in the carotid decreased in the patients as
a whole. The investigators documented a 38%
reduction in the volume of LRNC in the carotid
plaque; the LRNC fell from 14.2% to 7.4% of the
wall area in those regions. Importantly, they
demonstrated that the majority of delipidation
occurred in the first 2 years and then slowed
significantly in the third year. This is the first
prospective demonstration of the time course of
plaque delipidation with lipid lowering demon-
strated using noninvasive imaging.
There are some important limitations of the
study. We are not told what happened to the other
90 patients without lipid in their plaque. Did their
plaque progress or regress? How did their plaque
components change? The robustness and reproduc-
ibility of the LRNC measurements over multiple
time points have not been demonstrated and require
further validation. Issues related to image registra-
tion and partial volume-averaging artifacts could
potentially bias the results of this small dataset.
That is particularly crucial as, in the current study,
data from the internal carotid, carotid bulb, and
common carotid arteries were combined.
The authors also correlate the imaging findings
with lipid biomarkers and find relatively poor and
nonsignificant correlations. This study, therefore,
does not present a clear picture with regard to the
roles of such traditional measures with respect to
carotid MRI. Hence, the link between LDL low-
ering and plaque delipidation cannot be extracted
on the basis of the data presented in this study.
Most important, the treatment code is not yet
available for this study, so we do not know if 1 or 2
of the therapeutic arms showed more benefit than
the others or even if there was benefit in all 3 arms.
We cannot, therefore, draw any conclusion regard-lipidation. It should be noted that the 33 subjects
were allocated to 3 groups, resulting in small sample
sizes for each treatment. Therefore, this study may
also lack the power to discriminate any differences
between statin treatment compared to other lipid
reduction approaches with regard to plaque lipid
depletion. This is increasingly important given the
recently stopped AIM-HIGH (Atherothrombosis
Intervention in Metabolic syndrome with low
HDL/high triglycerides: Impact on Global Health
outcomes) trial in which niacin offered no clinical
benefit above statins in patients with a starting
low-density lipoprotein of approximately 70 (16).
We need to know the relative benefit of agents that
are potential add-ons to statins as, to date, the
imaging results of drugs such as ezetimibe have
been disappointing in this regard (7,17,18). Al-
though the ARBITER 6-HALTS (Arterial Biol-
ogy for the Investigation of the Treatment Effects
of Reducing Cholesterol 6: HDL and LDL Treat-
ment Strategies in Atherosclerosis) study (18) and
the Oxford Niaspan MRI study (6) suggested
plaque regression benefits of niacin that was not
borne out in the clinical results of the AIM-HIGH
trial (16).
Despite these limitations, the current study does
present the first in vivo evidence of the time course
of lipid depletion in carotid plaques in patients
undergoing lipid-lowering therapy. Most of this
effect is in the first 2 years. Is there a statute of
limitations on the delipidation benefits of plaque
regression therapies? More long-term serial studies
are needed to confirm this finding. In addition, the
present study by Zhao et al. (15) does not elucidate
the effect of various forms of lipid-lowering therapy
on plaque delipidation. Moreover, as no link could
be established between any changes in lipid bio-
markers and plaque delipidation, additional studies
with adequate statistical power are still needed to
better understand the mechanism of plaque com-
positional changes and their relationship to clinical
outcomes of atherosclerosis therapy.
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